Gemcitabine Cycles for Primary Peritoneal Cancer (PPC) and Ovarian Cancer (EOC)

1. Platinum-Sensitive Recurrent Disease (most common use of Gemcitabine)

Regimen: Carboplatin + Gemcitabine (GCIg Trial)

Regimen: Carboplatin + Gemcitabine + Bevacizumab (OCEANS Trial - preferred)

Per NCCN Guidelines (Version 3.2024) for Ovarian/Fallopian Tube/Primary Peritoneal Cancer: 6 cycles of platinum-based combination therapy is recommended for platinum-sensitive recurrent disease, with carboplatin/gemcitabine listed as a Category 1 option.

2. Platinum-Resistant or Refractory Disease (Gemcitabine Monotherapy)

Summary Table

Key Points

• The 6-cycle standard applies to platinum-sensitive recurrent disease in combination regimens
• Gemcitabine is not a first-line standard agent in most guidelines (paclitaxel + carboplatin remains preferred first-line), but may be substituted when paclitaxel is contraindicated (e.g., neuropathy)
• For newly diagnosed PPC/ovarian cancer, standard first-line is 6 cycles of carboplatin + paclitaxel; gemcitabine may replace paclitaxel in select cases
• Cycle length is typically 21 days in combination therapy

• Inj. Carboplatin 450 mg ✓
• Inj. Paclitaxel (Plexitel) 240 mg ✓
• Inj. Bevacizumab 400 mg (given for 4 cycles) ✓

Now for Recurrent Disease - New Regimen:

How Many Cycles?

Answer: 6 cycles of the Gemcitabine + Carboplatin combination

Important Conditions to Confirm Platinum-Sensitivity:

• Recurrence must be ≥6 months after completing last platinum (carboplatin) cycle
• If recurrence is <6 months - patient is platinum-resistant and this regimen is not appropriate (gemcitabine monotherapy or other non-platinum regimens would be used instead)

Cycle Schedule:

• Every 21 days (3-weekly)
• Gemcitabine given on Day 1 and Day 8 of each cycle
• Carboplatin and Bevacizumab on Day 1 only

Day 1 and Day 8 = ONE cycle ✅

One Cycle = 21 Days (3 weeks)

Think of it this way:

Day 1 + Day 8 together = 1 cycle Not 2 separate cycles.

So for 6 cycles total:

Carboplatin 450 mg in NS 500 mL - Assessment:

Diluent: ✅ CORRECT

• NS (Normal Saline 0.9%) is acceptable
• Dextrose 5% (D5W) is also acceptable
• NS 500 mL is the standard volume for this dose
• Final concentration = 450mg/500mL = 0.9 mg/mL ✅ (within safe range of 0.2-3.5 mg/mL)

Infusion Time: ⚠️ LONGER THAN NEEDED

• Minimum: 15 minutes
• Standard practice: 30 to 60 minutes
• Maximum required: 60 minutes
• No pre- or post-hydration required with carboplatin (unlike cisplatin)

Recommendation:

One Important Caution:

• Do NOT use aluminum-containing needles or IV sets - aluminum reacts with carboplatin and reduces its potency
• Watch for infusion reaction/hypersensitivity (especially from cycle 6 onwards - risk increases with repeat platinum exposure)
• Keep epinephrine, antihistamine, and corticosteroids ready at bedside during infusion

ECG Interpretation - Shaik Ayan, 17/Male (14 Jul 2026)

Patient Details

• Name: Shaik Ayan | Age: 17 years | Gender: Male
• Paper speed: 25 mm/s | Gain: 10 mm/mV (standard)

Step-by-Step Analysis

1. Rate

2. Rhythm

• P waves: Upright in I, II, aVF - Inverted in aVR ✅
• Every P wave followed by QRS ✅
• Regular rhythm ✅
• = Sinus Bradycardia

3. Intervals

4. Axis

5. Waveform Analysis

• Normal R-wave progression V1 to V6 ✅
• Transition zone at V3/V4 ✅ (normal)
• No LVH or RVH voltage criteria

• Isoelectric in all leads ✅
• No ST elevation or depression
• No signs of ischemia or injury ✅

• Upright in I, II, V3-V6 ✅
• Inverted in aVR ✅ (normal)
• Flat/slightly asymmetric in V1-V2 - this is a normal variant in young males (persistent juvenile T-wave pattern) ✅

Final Summary

Clinical Significance

1. Athletic/well-conditioned heart (most common) - increased vagal tone
2. High vagal tone during rest
3. Sleep/early morning recording

• Symptoms (dizziness, syncope, breathlessness)
• Rate dropping below 40 bpm
• Associated conduction disease

⚠️ This ECG interpretation is for clinical support only. Final interpretation should be made by a qualified physician in context of the patient's clinical presentation.